NIA's #1 Psychedelic Pick NUMI Hits New High!

On September 27th, NIA announced Numinus Wellness (TSXV: NUMI) at $0.285 per share as its #4 favorite overall stock suggestion for between now and year-end 2020 and #1 favorite psychedelic medicine stock suggestion. NUMI hit a high of $0.365 per share at 1:30PMEDT this afternoon for a gain of 28.07% from NIA's suggestion price!

On November 3rd, Oregon residents will be voting on a measure to create a program for legally administering psilocybin products, such as psilocybin-producing mushrooms to individuals aged 21 years or older.

NUMI has begun cultivating Psilocybe mushrooms, for the purpose of psilocybin production, at its 7000 square-foot Health Canada licensed facility. After industry bellwether Compass Pathways (CMPS), which now has a market cap of $1.52 billion, we consider NUMI to be the highest quality psychedelics company. NUMI's vertically integrated ecosystem positions it to be a first-in-market, trusted leader in the delivery of psychedelic-assisted psychotherapies when regulated.

If you would like to be the first to receive any of our future psychedelic stock suggestions, sign-up for the free PsychStocks newsletter at

Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. NIA has been compensated by NUMI USD$30,000 cash for a six-month marketing contract. This message is meant for informational and educational purposes only and does not provide investment advice.